| Not Yet Recruiting | This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autol NCT07412405 | GUSTAVO SALGUERO | N/A |
| Recruiting | This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma NCT07121946 | LTZ Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Cli NCT07264894 | Zhengzhou University | Phase 4 |
| Recruiting | Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cel NCT07285590 | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Phase 2 |
| Recruiting | Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma NCT07077512 | Sun Yat-sen University | Phase 2 |
| Recruiting | Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease NCT07272499 | Ruijin Hospital | Phase 2 |
| Recruiting | Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma NCT07257510 | Peking University Third Hospital | N/A |
| Not Yet Recruiting | JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma NCT07024147 | Peking University Cancer Hospital & Institute | Phase 1 |
| Recruiting | Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment NCT07199296 | Ruijin Hospital | Phase 2 |
| Recruiting | Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantl NCT06846489 | Sun Yat-sen University | Phase 2 |
| Recruiting | A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the NCT06788652 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | — |
| Recruiting | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment NCT06496308 | Ruijin Hospital | Phase 3 |
| Recruiting | Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma NCT06464861 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Active Not Recruiting | A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lympho NCT05951959 | AstraZeneca | Phase 2 |
| Recruiting | Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms NCT06043011 | iOMEDICO AG | — |
| Completed | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R NCT05665530 | Prelude Therapeutics | Phase 1 |
| Recruiting | CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms NCT06593145 | FamiCordTx | Phase 1 |
| Active Not Recruiting | A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma NCT05716087 | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 2 |
| Terminated | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma NCT05720052 | MingSight Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Recruiting | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NCT05131022 | Nurix Therapeutics, Inc. | Phase 1 |
| Terminated | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma NCT05144347 | Exelixis | Phase 1 |
| Recruiting | Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients NCT05098613 | University of Colorado, Denver | Phase 1 |
| Recruiting | DALY II USA/ MB-CART2019.1 for DLBCL NCT04792489 | Miltenyi Biomedicine GmbH | Phase 2 |
| Recruiting | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137 | Nurix Therapeutics, Inc. | Phase 1 |
| Unknown | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies NCT04767308 | Huazhong University of Science and Technology | EARLY_Phase 1 |
| Completed | Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T NCT04488354 | Calibr, a division of Scripps Research | Phase 1 |
| Unknown | Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > NCT05406154 | Peking University Third Hospital | — |
| Completed | Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Re NCT04477486 | AbbVie | Phase 2 |
| Recruiting | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies NCT04186520 | Medical College of Wisconsin | Phase 1 / Phase 2 |
| Active Not Recruiting | ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) NCT04049513 | Malaghan Institute of Medical Research | Phase 1 |
| Completed | A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma NCT03877055 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Recruiting | REal World Data in LYmphoma and Survival in Adults NCT03869619 | Hospices Civils de Lyon | — |
| Terminated | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Dif NCT03571828 | Amgen | Phase 1 |
| Terminated | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML NCT03547115 | MEI Pharma, Inc. | Phase 1 |
| Unknown | Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 NCT03265158 | Royal Marsden NHS Foundation Trust | — |
| Terminated | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma NCT02914938 | MEI Pharma, Inc. | Phase 1 |
| Active Not Recruiting | A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL NCT02717624 | Acerta Pharma BV | Phase 1 |
| Active Not Recruiting | An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma NCT02213926 | Acerta Pharma BV | Phase 2 |
| Completed | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies NCT02362035 | Acerta Pharma BV | Phase 1 / Phase 2 |